Benralizumab resulted in a 45-51% reduction in exacerbation rates compared to placebo (reduction from 3.0 to 0.73 per year for treatment every 4 weeks; ...

Benralizumab is noninferior to mepolizumab in achieving remission of relapsing or refractory eosinophilic granulomatosis with polyangiitis at 36 and 48 weeks, according to data published in The ...

Gastroenterology > General Gastroenterology Benralizumab Led to Histologic Responses in Eosinophilic Esophagitis — But there was no significant difference in symptom relief compared with placebo ...

Benralizumab is an anti-eosinophil monoclonal antibody that induces direct, rapid and near-complete depletion of eosinophils, with an onset of action within 24 hours as confirmed in early phase I ...

BOSTON — Patients taking benralizumab experienced more asthma exacerbations than patients taking mepolizumab, according to an abstract presented at the CHEST Annual Meeting. This study compared ...

Benralizumab is a type of drug called an interleukin-5 receptor alpha-directed cytolytic monoclonal antibody. It is approved by the FDA for the treatment of severe eosinophilic asthma.

A year's course of benralizumab injections has led to a significant decrease in the frequency of asthma exacerbations -- cutting the rate of exacerbations by a third to a half compared with ...

At both weeks 36 and 48, the benralizumab group exhibited an adjusted remission rate of 59.2%, while the mepolizumab group demonstrated a rate of 56.5% (difference, 2.71%; 95% CI, -12.54 to 17.96 ...

Benralizumab, an interleukin-5 (IL-5) antagonist used to treat severe asthma, does not weaken antibody response of influenza vaccinations, according to results of a recent study.

Benralizumab is marketed under the trade name Fasenra (AstraZeneca) and is currently indicated as an add-on maintenance treatment of severe asthma in patients aged ≥12 years, ...

Benralizumab, which was approved as an add­-on maintenance treatment for patients with severe eosinophilic asthma, is an eosinophil-depleting monoclonal antibody.

A year's course of benralizumab injections has led to a significant decrease in the frequency of asthma exacerbations - cutting the rate of exacerbations by a third to a half compared with placebo ...